All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?
What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?
In this video, Zeiser explains the mechanism of action of glucagon-like peptide-2 (GLP-2), an enteroendocrine peptide produced by L cells. Studies in mice have shown intestinal GLP-2 levels are reduced in acute (a)GvHD, and similarly in patients developing GvHD. The use of the GLP-2 analog, teduglutide, reduces de novo aGvHD and steroid-refractory aGvHD in different mouse models. Teduglutide may also be effective in patients with steroid-refractory aGvHD.
Editorial Theme | Novel therapies for the treatment of GvHD
Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...
Response to MSC treatment at one week predicts probability of survival in patients with acute graft-versus-host disease
This analysis showed that clinical responses at week 1 following MSC treatment may be a feasible early predictor of clinical...
Subscribe to get the best content related to GvHD delivered to your inbox